Imolast

Timolol maleate and Latanoprost, the active ingredients in Imolast, are a beta‑blocker and prostaglandin analog presented as eye drops for ocular use. They lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. GNH USA supplies Imolast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imolast is indicated for conditions affecting ocular fluid dynamics and intra‑ocular pressure. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: lowers pressure to prevent progression to glaucoma. - Pseudoexfoliative glaucoma: helps control pressure in this secondary open‑angle form.

Imolast may cause ocular and systemic reactions.

Common Side Effects: - Blurred vision: transient visual disturbance after instillation. - Eye irritation: burning or stinging sensation. - Conjunctival hyperemia: mild redness of the eye. - Itching or foreign‑body sensation. - Increased eyelash growth. - Mild eyelid pigmentation changes.

Serious or Rare Side Effects: - Significant ocular inflammation or uveitis. - Severe allergic reaction: swelling, rash, or difficulty breathing. - Permanent iris color change. - Worsening of glaucoma despite therapy. - Systemic β‑blocker effects: bradycardia, hypotension, bronchospasm. - Corneal edema or persistent visual loss.

Before prescribing Imolast, clinicians should consider several safety aspects. - Monitor intra‑ocular pressure: schedule regular pressure checks. - Assess for β‑blocker contraindications: asthma, COPD, severe bradycardia. - Avoid concurrent ocular medications: separate dosing times to prevent interactions. - Use caution in pregnancy: limited safety data, weigh benefits against risks. - Remove contact lenses before instillation: lenses may retain drug and cause irritation. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Imolast can interact with other systemic and ocular agents.

Major Interactions (Avoid): - Systemic β‑blockers: additive bradycardia or hypotension. - Other prostaglandin analog eye drops: increased risk of ocular side effects. - Monoamine oxidase inhibitors (MAOIs): potential systemic cardiovascular effects.

Moderate Interactions (Monitor Closely): - Topical anesthetic drops: may heighten corneal toxicity. - Anticholinergic eye drops: could alter pupil response and affect pressure control.